A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1343 participants.

Also called NCT04197479

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,343 participants (enrolled count) (from the registry)
Sponsor
Madrigal Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT04197479
Other papers using this trial's data
  • Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial Nature medicine, 2023-11 DOI, PubMed 37845512, PMC10667098 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04197479. Randomized; quadruple masking; primary purpose treatment. Start 2019-12-16 (actual); primary completion 2023-01-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Acronym
MAESTRO-NAFLD1
Condition
Non-Alcoholic Fatty Liver Disease
Intervention (Drug)
Placebo
Intervention (Drug)
Resmetirom
Lead sponsor
Madrigal Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04197479
Content hash
87da3871c58dd446a25b27a29321881aedaa9cfbdaac2e77bd1d5dff57288f4a